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for any avoided severe complication. In the univariate sensitivity analysis the ICER 
result was especially sensible to CA total cost and in a lesser extension to MICS total 
costs. The probabilistic sensitivity analysis shows the robustness of the results. The 
37.8% of the results were cost saving respect to CA. The Willingness To Pay (WTP) 
acceptability curves show that MICS compared to CA, had a higher probability to be 
accepted for the all the WTP values above US$16.000. ConClusions: MICS shows 
a better cost-effectiveness ratio than CA, with an ICER of US$8.326. The univariate 
sensitivity analysis shows the ICER result was especially sensible to CA total costs. 
The probabilistic analysis shows that in 36.8% of Monte Carlo simulations, MICS 
was cost saving respect to CA.
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objeCtives: To compare clopidogrel/aspirin with ticagrelor/aspirin in terms of 
costs and effects, from the perspective of the Mexican public health care sys-
tem. Methods: A markov model was designed to take into account all relevant 
outcomes reported in the PLATO study, allowing the evaluation of two differ-
ent cohorts of patients according to their renal function (< 60 mL/min creatinine 
clearance and ≥ 60 mL/min). The effectiveness measures analyzed were life years 
gained and events (bleeding, stroke and MI) averted. Annual cost of antiplatelet 
therapy was estimated with unit prices of the IMSS, while costs of diseases were 
taken from DRGs of the IMSS. 5 years horizon was used, so future costs were dis-
counted at 5% discount rate. Probabilistic sensitivity analysis was performed with 
1000 iterations via Monte Carlo simulations. Results: Total expected costs per 
patient were US$17,121 and US$17,697 respectively for both cohorts of clopidogrel 
while the costs for the two cohorts of ticagrelor were US$18,430 and US$18,261 
respectively. The treatment with clopidogrel resulted in less outcomes per patient 
(bleeding: 0.67 and 0.55; stroke: 0.09 and 0.083; MI: 0.51 and 0.49) than ticagrelor 
(bleeding: 0.76 and 0.59; stroke: 0.1 and 0.085; MI: 0.53 and 0.5); therefore the 
pharmacoeconomic profile of clopidogrel in comparison with ticagrelor is more 
favorable in the current study. Sensitivity analysis showed that clopidogrel has a 
higher probability of being a cost-saving option versus ticagrelor for both cohorts 
of patients. ConClusions: The economic evaluation of clopidogrel/aspirin ver-
sus ticagrelor/aspirin, taking into account relevant outcomes as well as primary 
endpoints of clinical trials, has proven that cost-effectiveness results may vary 
depending of the renal function of patients, thus giving a broader picture of the 
problem to decision makers.
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objeCtives: To compare the incremental cost-effectiveness ratio (ICER) of the 
reversible direct thrombin inhibitor dabigatran 150mg BID with those of the Xa 
factor inhibitors rivaroxaban and apixaban from the Mexican public health insti-
tution perspective. Methods: The ICER´s were calculated using a Markov model 
with a 10-year time horizon for patients over 65 and diagnosed with atrial fibril-
lation. Each treatment arm started with a cohort of 10,000 patients. The clinical 
events tracked were incorporated: ischemic stroke, systematic embolism, transient 
ischemic stroke, hemorrhagic stroke, intracranial hemorrhage, extracranial hemor-
rhage, acute myocardial infarction, minor bleed and death. Transition probabilities 
were calculated based on indirect comparisons of published phase III clinical tri-
als. Costs are adapted to the Mexican public health institution perspective. Costs 
were calculated using published literature, and national costs taken from pharma-
ceutical companies and public health institutions. Cost-effectiveness was based 
on the 1GDP per capita threshold established by the National Health Council in 
Mexico. Costs and outcomes were discounted at a 5% annual-rate. Deterministic 
and probabilistic sensitivity analyses were performed to evaluate the uncertainty 
of the variables. Results: Dabigatran was found to be dominant when compared 
with rivaroxaban and apixaban. A reduction on risk for cardiovascular complica-
tions was the key advantage of dabigatran. Dabigatran was also more effective when 
compared with warfarin (69,435 vs. 68,373 life years gained) although more costly 
(USD$192.76 vs USD$190.73 million dollars). The ICER was USD $1,910.43 per life year 
which is considered highly cost-effectiveness. The Incremental Cost-Utility Ratio per 
QALY gained was USD$1,549.00. ConClusions: The ICER and ICUR of Dabigatran 
are well below 1GDP (USD$ 10,483.26) per capita versus warfarina. Dabigatran was 
found to be dominant in comparison with all other treatments. As such, dabigatran 
can be considered a very cost-effective intervention for the Mexican population 
over 65 with atrial fibrillation.
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objeCtives: To identify the incremental cost-effectiveness ratio (ICER) for the 
treatment of inoperable patients with severe symptomatic aortic valve stenosis 
(SAS) using transcatheter aortic valve replacement (TAVR), compared to the stand-
ard of care (SoC), from the Mexican public payer perspective. Methods: A previ-
ously published decision analytical model was adapted to the Mexican setting to 
predict clinical endpoints and costs over 10 years and discounted at 5%. Mexican 
epidemiological data were applied. We performed a systematic review of published 
clinical trials to obtain the necessary clinical information to evaluate the impact 
of TAVR and SoC in the short and long term evolution of patients. Direct public 
health care costs were estimated from published literature and governmental data-
bases. Resource utilization patterns were derived from Mexican Clinical Practice 
Guidelines. The ICER was computed as incremental cost per life-year gained (LYG). 
Probabilistic and deterministic sensitivity analyses were conducted to estimate 
the confidence around the results. Results: Over the time horizon, compared 
to SoC, TAVR produced an additional 1.61 Life years at an additional cost to the 
health care sector of $777,414 MXP. The ICER was thus $483,022 MXP (35,779 USD) 
per LYG. The sensitivity analysis identified time horizon, discount rate on health 
benefits, probability of leaving intensive care and time of stay in intensive care, 
as the variables with the most impact. The model was insensitive to changes in 
the TAVR acquisition cost, device related complication rates and the probability/ 
cost of additional pacing. ConClusions: In comparison with SoC, TAVR produces 
an increase in life expectancy in patients with SAS that are ineligible for cardiac 
surgery, at an ICER below an internationally accepted cost-effectiveness threshold 
value. These results, and the improvements in health and quality of life observed 
in the clinical studies, identify TAVR as both a clinically effective and cost-effective 
therapy for Mexican patients.
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objeCtives: Atrial Fibrillation (AF) affects 1–2% of the population, and this figure 
is likely to increase in the next 50 years. AF is associated with increased rates of 
death, stroke and other thromboembolic events, heart failure and hospitaliza-
tions, degraded quality of life and reduced exercise capacity. It is suggested that 
patients with AF should be stratified for the risk of stroke and bleedings and that 
most should receive antithrombotic therapy. The aim of this study was to assess 
the cost-effectiveness (CE) of Apixaban against other anticoagulation therapies for 
prevention on non-valvular atrial fibrillation (NVAF), from the private health care 
perspective. Methods: A simulated cohort of 1000 patients with NVAF entered 
a decision-tree model to compare costs and effectiveness of Warfarin (5 mg/24 
hours), Apixaban (5 mg/12 hours), Dabigatran (110 mg/12 hours and 150 mg/12 
hours), and Rivaroxaban (20 mg/24 hours). Effectiveness measures were: stroke, 
bleeding, myocardial infarction (MI) rates and deaths. Local costs were gathered 
from Guatemala’s official databases (US$, 2013) and only direct medical costs were 
considered. The model used a lifetime horizon with a 5% discount. Results: 
Apixaban was the only treatment that consistently prevented all four consid-
ered diseases: 3 MIs, 4 strokes, 85 bleedings and 1 SE avoided when compared to 
Warfarin. Overall costs were US$33708.34 for warfarin, US$24538.68 for Apixaban, 
US$24757.57 for Dabigatran 110 mg, US$24198.23 for Dabigatran 150 mg, and 
US$24252.46 for Rivaroxaban. In terms of QALY’s, Apixaban earned the highest 
amount with 5.740, followed by Rivaroxaban, Dabigatran 150 mg, Dabigatran 110 
mg and Warfarin. In the CE incremental analysis, Apixaban was a cost-effective 
option. Apixaban obtained the highest probability of being cost-effective (45%) 
with a 3 GPB per capita in Guatemala. ConClusions: Apixaban is a Cost-Effective 
option for the Guatemala’s Private Health System.
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objeCtives: To evaluate the cost-effectiveness of rivaroxaban in addition to the 
standard of care (SoC) therapy in the prevention of the risk of CV events and 
bleeding in patients with a recent ACS compared to the placebo in addition to the 
SoC. Methods: A Markov model demonstrating the progression of ACS patients 
from healthy state towards atherosclerotic and bleeding events and to death was 
adapted to the Turkish setting. The cycle length was set as six-months. The analy-
sis was undertaken from a payer perspective. Event rates and treatment effects 
were derived from the ATLAS-2-TIMI clinical trial. 61Utility values for events were 
based on international literature. Costs of each health state included year 2013 
local costs of medications, monitoring and events (TL/ USD currency rate was set 
at 1.70; mid 2013). Incremental cost effectiveness ratios (ICER) per life year (LY) and 
quality-adjusted LY (QALY) gained were calculated. One-way sensitivity analyses 
were conducted to test the robustness of the model. The time horizon was life time 
period. Discount rate was set at 3.5% for economic and clinical inputs. Willingness-
to-pay (WTP) threshold was set as twice the local gross domestic product per 
capita (20,888USD). Results: The total cost of rivaroxaban-treated patients was 
578USD higher compared to SoC. Additional drug costs (676USD) caused by rivar-
oxaban was somewhat offset by reduced costs of and events and interventions 
(98USD). Moreover, rivaroxaban was associated with increments of 0.102LYs and 
0.088QALY leading to an ICER of 5,691USD/LY gained and 6,590USD/QALY gained. 
Sensitivity analyses showed that the cost-effectiveness results are fairly insensi-
tive to most inputs. ConClusions: Rivaroxaban, given its cost-saving effects on 
consequent CV events, improvement in LYs and QALYs, and ICER values below 
WTP threshold, is suggested to be a cost-effective alternative for the prevention 
of CV events in ACS.
